Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

This study is testing a combination of nab-sirolimus (a targeted drug that blocks a cancer growth pathway called mTOR) and letrozole (a hormone-blocking drug) for women with advanced or recurrent endometrioid endometrial cancer (a type of uterine cancer). **You may be eligible if...** - You have confirmed advanced or recurrent endometrioid endometrial carcinoma (a specific type of uterine cancer) that cannot be removed with surgery - You have at least one measurable tumor on a scan - You have received prior treatment for this cancer (specific prior treatment history required) **You may NOT be eligible if...** - You have a different type of uterine cancer (not endometrioid) - You have no measurable disease on imaging - You have not received prior therapy as specified by the study criteria Talk to your doctor to see if this trial is right for you.